8-K: Seres Therapeutics Reports Q4/FY25 Results, Advances Pipeline

Seres Therapeutics announced its Q4 and full-year 2025 financial results, highlighting a shift to net income from continuing operations and progress in its inflammatory and immune disease pipeline.

Summary

• Net income from continuing operations was $5.7 million for the full year 2025, a significant improvement from a net loss of $125.8 million for 2024.
• Net loss from continuing operations for the fourth quarter of 2025 was $15.3 million, compared to $15.7 million for the same period in 2024.
• Research and development (R&D) expenses decreased to $49.1 million for FY25 from $64.6 million for FY24, driven by lower personnel, platform investments, and SER-155 program expenses.
• General and administrative (G&A) expenses decreased to $39.2 million for FY25 from $53.2 million for FY24, primarily due to reduced personnel, professional fees, and facility costs.
• Cash and cash equivalents totaled $45.8 million as of December 31, 2025, including $12.2 million from an at-the-market equity offering in Q4 2025.
• The company expects to fund operations through the third quarter of 2026.
• Operational focus is on advancing live biotherapeutic programs for inflammatory and immune diseases, including SER-603 for inflammatory bowel disease (IBD) and SER-155 for immune checkpoint-related enterocolitis (irEC).
• Clinical data from the fully enrolled investigator-sponsored study evaluating SER-155 for irEC is expected in Q2 2026.
• The SER-155 program for preventing serious bloodstream infections in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients is Phase 2 ready, pending funding.
• Seres is actively seeking partnerships and other funding sources to support pipeline advancement and value creation.
• New insights into the functional mechanism and clinical impact of VOWST and SER-155 were highlighted in recent publications in Nature Medicine and the Journal of Infectious Diseases.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update due to the significant improvement in net income from continuing operations and promising clinical data for SER-155, offset by a short cash runway and dependency on external funding for key pipeline progression.

Positives

• Achieved net income from continuing operations of $5.7 million for the full year 2025, a substantial improvement from a $125.8 million net loss in 2024.
• Operating expenses were significantly reduced, with R&D decreasing by $15.5 million and G&A by $14 million year-over-year, demonstrating effective cost management.
• Received $75 million in installment payments from Nestle in 2025 related to the VOWST asset sale.
• SER-155 Phase 1b study showed a 77% relative risk reduction in bloodstream infections and a significant reduction in systemic antibiotic use in allo-HSCT patients, with a placebo-like safety profile.
• SER-155 has received Breakthrough Therapy and Fast Track designations, indicating regulatory recognition of its potential.
• The investigator-sponsored trial for SER-155 in immune checkpoint-related enterocolitis (irEC) is fully enrolled, with clinical data expected in Q2 2026, addressing a serious condition with a sizable commercial opportunity.
• Advancing preclinical stage candidates like SER-603 for IBD, with IND-enabling activities underway and engagement with potential collaborators.

Negatives

• The company's current cash position is expected to fund operations only through the third quarter of 2026, indicating a short cash runway.
• The SER-155 Phase 2 study for allo-HSCT is 'Phase 2 ready, pending receipt of funding,' highlighting a critical dependency on external capital to progress.
• Ongoing efforts to secure additional funding through partnerships or other sources are necessary to support pipeline advancement and extend the cash runway.

Risks

• Need for additional funding to support operations and pipeline development.
• Ability to continue as a going concern is uncertain given current financial position.
• Significant accumulated losses and no current profitability, with no guarantee of future profitability.
• Cost reduction actions may not achieve their intended benefits, including an extended cash runway.
• Limited operating history as a focused live biotherapeutics company.
• Expected payments from the VOWST sale are subject to risks and uncertainties.
• May not realize the anticipated benefits of the VOWST sale and could face new challenges as a smaller, less diversified company.
• Potential to receive notice of failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC.
• The novel approach to therapeutic intervention carries inherent development and regulatory risks.
• Reliance on third parties to conduct clinical trials and manufacture product candidates.
• Ability to achieve market acceptance necessary for commercial success of product candidates.
• Significant competition in the biotechnology and therapeutic markets.
• Ability to protect intellectual property rights.
• Impact of recent management transitions and appointments and the ability to retain key personnel.
• Disruptions at the FDA or other government agencies could affect regulatory timelines.

Future Outlook

Seres Therapeutics is focused on advancing its inflammatory and immunology biotherapeutics portfolio, including SER-603 for IBD and SER-155 for irEC and allo-HSCT. Clinical data from the SER-155 irEC study is expected in Q2 2026. The SER-155 allo-HSCT program is Phase 2 ready, contingent on securing funding. The company is actively seeking partnerships and other funding sources to support pipeline development and extend its cash runway, which is projected through Q3 2026.

Management Comments

• "We are prioritizing our promising inflammatory and immunology biotherapeutics portfolio, including SER-603 for inflammatory bowel disease." Richard Kender, Executive Chair and interim CEO.
• "We are on track to report clinical data from the fully enrolled investigator-sponsored study at Memorial Sloan Kettering Cancer Center evaluating SER-155 to treat immune checkpoint inhibitor-related enterocolitis in the second quarter of this year." Richard Kender.
• "This serious condition affects up to 50% of immune checkpoint-treated cancer patients, with rates varying based on cancer drug and treatment regimen, and represents a sizable therapeutic and commercial opportunity." Richard Kender.
• "Additionally, our SER-155 program for the prevention of serious bloodstream infections in patients undergoing allo-HSCT for blood cancer is Phase 2 ready, and we continue to seek funding to support further development." Richard Kender.
• "To advance these opportunities, we continue to judiciously manage our resources, focusing on progressing our prioritized programs, as we pursue partnerships and other funding sources." Richard Kender.
• "We are in discussion with collaborators who could potentially provide Seres with additional financial and other resources to support pipeline advancement and value creation." Richard Kender.

Industry Context

StockSavvy.ai notes that Seres Therapeutics is navigating a challenging but potentially lucrative space in live biotherapeutics, particularly for inflammatory and immune diseases. The divestiture of VOWST to Nestle Health Science allows for a focused strategy on its emerging pipeline, a common move for biotech companies to streamline operations and conserve capital. The focus on conditions like irEC and allo-HSCT infections addresses significant unmet medical needs with high morbidity and mortality, positioning Seres in areas with substantial commercial potential if successful. The pursuit of partnerships for funding is a standard industry practice for clinical-stage biotechs to de-risk development and extend runway.

Comparison to Industry Standards

• SER-155's 77% relative risk reduction in bloodstream infections in allo-HSCT patients, coupled with a placebo-like safety profile, positions it as a potentially superior alternative to existing prophylaxis. This efficacy profile compares favorably to Prevymis (letermovir), which generated $785 million in 2024 worldwide sales for viral infection prophylaxis in medically vulnerable patients.
• The estimated cost of allo-HSCT procedures (around $400,000 US in year 1 per patient) and the additional $180,000 cost due to complications like infections highlight the significant economic burden that an effective preventative therapy like SER-155 could alleviate, aligning with industry trends towards value-based healthcare.
• The company's strategy to leverage its 'AI-enabled MbTx Platform' for discovery and optimization of live biotherapeutics is consistent with broader biotech industry trends of integrating advanced computational methods to accelerate drug development and identify novel targets.

Management Changes

Related Party Transactions

• Accounts receivable due from SPN (related party) decreased from $2,068,000 in 2024 to $360,000 in 2025.
• Accrued liabilities due to SPN (related party) decreased from $17,750,000 in 2024 to $3,278,000 in 2025.
• Manufacturing Services expenses of $6.5 million for 2025 (vs. $3.5 million in 2024) relate to the provision of manufacturing services under the transition services agreement with Nestlé.
• Reimbursement received from SPN (related party) for transition services was $13,311,000 for 2025 (vs. $6,292,000 in 2024).

Stakeholder Impact

• Shareholders: Potential for increased value from pipeline progression and successful partnerships, but dilution risk from future capital raises and ongoing operational losses. Improved financial performance from continuing operations is a positive signal.
• Employees: Focus on prioritized programs and cost management may imply workforce adjustments, though not explicitly stated. Management changes indicate a strategic shift.
• Customers (future patients): Potential for novel live biotherapeutics to address significant unmet medical needs in inflammatory and immune diseases, offering new treatment options for severe conditions like irEC and allo-HSCT infections.
• Creditors: Improved financial results from continuing operations and receipt of Nestle payments could enhance creditworthiness, but the short cash runway remains a concern.
• Partners (Nestle Health Science): Continued collaboration through the transition services agreement and potential future milestone payments from the VOWST sale.

Next Steps

• Report clinical data from the investigator-sponsored SER-155 study in immune checkpoint-related enterocolitis (irEC) in Q2 2026.
• Secure funding to commence the Phase 2 study for SER-155 in allogeneic hematopoietic stem cell transplant (allo-HSCT).
• Conduct IND-enabling activities for SER-603.
• Engage potential collaborators for SER-603 clinical advancement as a monoor combination therapy for IBD.
• Evaluate further opportunities to extend the cash runway beyond Q3 2026.
• File the Annual Report on Form 10-K with the SEC on March 12, 2026.

Key Dates

Recommendation

The company shows promising clinical data for SER-155 and a significant improvement in net income from continuing operations due to cost reductions and Nestle payments. However, the short cash runway through Q3 2026 and the dependency on securing additional funding for key Phase 2 trials introduce substantial financial risk. While the pipeline has potential, the immediate need for capital suggests a 'Hold' recommendation until further clarity on funding and partnership agreements emerges.

Keywords

Seres Therapeutics, MCRB, live biotherapeutics, inflammatory diseases, immune diseases, SER-155, SER-603, immune checkpoint inhibitor-related enterocolitis, allo-HSCT, inflammatory bowel disease, IBD, biotechnology, clinical-stage, financial results, Q4 2025, full year 2025, microbiome, VOWST, Nestle Health Science, oncology, bloodstream infections, cash runway, partnerships, R&D, G&A